Jury selection kicks off in Musk v. Altman trial

Jury selection has begun in Elon Musk’s lawsuit against OpenAI, Sam Altman and Greg Brockman, with the liability phase expected to run through mid-May and a possible remedies phase starting May 18. Musk is seeking to unwind OpenAI’s restructuring and has previously asked for up to $134 billion in alleged wrongful gains, while only two claims remain: unjust enrichment and breach of charitable trust. The case adds legal overhang for OpenAI and comes as both OpenAI and xAI sit at the center of the AI and private-markets race.

Analysis

This is less a binary liability event than a sequencing event for governance risk across the private AI complex. Even a narrow adverse finding would likely matter more through the remedies phase than the verdict itself, because the judge can effectively reprice control, capital structure, and strategic flexibility without needing a jury to bless the full damage theory. That creates a two-step catalyst: short-dated headline volatility now, then a more important repricing window if the court signals any willingness to unwind or constrain the nonprofit-control architecture.

The second-order effect is on dealability, not just litigation optics. If OpenAI’s structure is perceived as judicially fragile, partner negotiations with hyperscalers, chip suppliers, and enterprise customers become harder because counterparties will price in execution risk, not just model risk. That could advantage competitors with cleaner governance and simpler IPO pathways, particularly those that can market themselves as more predictable public-market assets once capital becomes scarce or more expensive.

The market is also likely underestimating how much this trial can change private-market marks before any final damages number is known. If the court even modestly pressures the current restructuring, the implication is that the company’s near-term IPO narrative shifts from growth story to governance overhang, compressing the multiple versus other late-stage AI assets. Conversely, if the judge narrows relief and preserves the structure, the short squeeze in governance-risk hedges could be violent because a lot of negative optionality is embedded in the setup.

The contrarian view is that the base case is not a clean win or loss, but a negotiated judicial middle ground that produces limited operational change and a lot of noise. That means the better trade is not directional on the lawsuit outcome alone; it is relative value between names with similar AI exposure but different governance complexity. In that framing, the real winner is the cleanest public-market path to AI monetization, not necessarily the largest model developer.

Key Decisions for Investors

• Buy 1-2 month downside protection on private AI/AI-proxy exposure via QQQ or SMH puts into the remedies window; the skew is attractive because headline risk is front-loaded while the court’s ability to alter structure creates tail risk that is not fully reflected in implied vol.
• Pair trade: long a cleaner AI platform beneficiary with public-market simplicity vs. short a governance-sensitive AI winner on any strength over the next 2-6 weeks; the thesis is multiple compression on structure risk rather than earnings risk.
• If the court signals willingness to unwind or constrain the nonprofit-control arrangement, add to short-dated vol long exposure in high-beta AI hardware suppliers for 3-5 trading days, as capital-allocation uncertainty tends to widen supplier beta even when fundamentals are unchanged.
• If the liability phase appears contained, fade any knee-jerk selloff in large-cap AI leaders and rotate into the most structurally levered names; the market may have priced a much worse remedies outcome than the judge is likely to deliver.
• Avoid initiating fresh outright longs in names whose investment case depends on imminent IPO rerating until the remedies hearing passes; the better entry is after the court clarifies whether governance will remain an overhang or become a headline-only event.